Search results

1971 results

Sorted by Date . Sort by Relevance

  1. Hysteroscopic sterilisation by insertion of intrafallopian implants (IPG587)

    October 2017: The device used in this procedure (Essure) no longer has a CE mark. The CE mark is necessary for medical devices to be used in EU countries. Therefore NICE has decided to suspend its guidance. NICE would consider whether to issue new guidance on “Hysteroscopic sterilisation by insertion of intrafallopian implants” should evidence including an appropriately CE marked device become available.

  2. Immunosuppressive therapy for kidney transplant in children and young people (TA482)

    Evidence-based recommendations on immunosuppressive therapy for kidney transplant in children and young people

  3. Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma (TA478)

    Evidence-based recommendations on brentuximab vedotin (Adcetris) for treating relapsed or refractory systemic anaplastic large cell lymphoma in adults

  4. Autologous chondrocyte implantation for treating symptomatic articular cartilage defects of the knee (TA477)

    Evidence-based recommendations on autologous chondrocyte implantation (ACI) in people with symptomatic articular cartilage defects of the knee

  5. Intramuscular diaphragm stimulation for ventilator-dependent chronic respiratory failure caused by motor neurone disease (IPG593)

    Evidence-based recommendations on intramuscular diaphragm stimulation for ventilator-dependent chronic respiratory failure in people with motor neurone disease

  6. Intramuscular diaphragm stimulation for ventilator-dependent chronic respiratory failure caused by high spinal cord injuries (IPG594)

    Evidence-based recommendations on intramuscular diaphragm stimulation for ventilator-dependent chronic respiratory failure caused by high spinal cord injuries

  7. Cetuximab and panitumumab for previously untreated metastatic colorectal cancer (TA439)

    Evidence-based recommendations on cetuximab (Erbitux) and panitumumab (Vectibix) for previously untreated RAS wild-type metastatic colorectal cancer in adults

  8. Ab externo canaloplasty for primary open-angle glaucoma (IPG591)

    Evidence-based recommendations on ab externo canaloplasty (widening eye’s main draining canal) for primary open-angle glaucoma (damaged optic nerve)

  9. High-intensity focused ultrasound for symptomatic breast fibroadenoma (IPG592)

    Evidence-based recommendations on high-intensity focused ultrasound for symptomatic breast fibroadenoma (benign/non-cancerous lumps in the breast)

  10. Pembrolizumab for advanced melanoma not previously treated with ipilimumab (TA366)

    Evidence-based recommendations on pembrolizumab (Keytruda) for treating advanced melanoma in adults who have not had ipilimumab

  11. Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab (TA357)

    Evidence-based recommendations on pembrolizumab (Keytruda) for treating advanced melanoma after disease progression with ipilimumab in adults

  12. Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy (TA428)

    Evidence-based recommendations on pembrolizumab (Keytruda) for locally advanced or metastatic PD-L1-positive non-small-cell lung cancer (NSCLC) in adults

  13. Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer (TA476)

    Evidence-based recommendations on paclitaxel as albumin-bound nanoparticles (nab-paclitaxel; Abraxane) for untreated metastatic pancreatic cancer in adults

  14. Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck (TA473)

    Evidence-based recommendations on cetuximab (Erbitux) for treating recurrent or metastatic squamous cell cancer of the head and neck in adults

  15. Biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancer (IPG590)

    Evidence-based recommendations on biodegradable spacer insertion (gel or balloon) to reduce rectal toxicity during radiotherapy for prostate cancer in adults

  16. Holoclar for treating limbal stem cell deficiency after eye burns (TA467)

    Evidence-based recommendations on Holoclar for treating limbal stem cell deficiency in adults after eye burns

  17. Pemetrexed for the maintenance treatment of non-small-cell lung cancer (TA190)

    Evidence-based recommendations on pemetrexed disodium (Alimta) for the maintenance treatment of non-small-cell lung cancer (NSCLC)

  18. Asfotase alfa for treating paediatric-onset hypophosphatasia (HST6)

    Evidence-based recommendations on asfotase alfa (Strensiq) for treating paediatric-onset hypophosphatasia in adults and children

  19. Laparoscopic insertion of a magnetic titanium ring for gastro-oesophageal reflux disease (IPG585)

    Evidence-based recommendations on laparoscopic insertion of a magnetic titanium ring for gastro-oesophageal reflux disease (GORD) in adults

  20. Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma (TA462)

    Evidence-based recommendations on nivolumab (Opdivo) for treating relapsed or refractory classical Hodgkin lymphoma in adults

  21. Roflumilast for treating chronic obstructive pulmonary disease (TA461)

    Evidence-based recommendations on roflumilast (Daxas) for treating chronic obstructive pulmonary disease (COPD) in adults with chronic bronchitis

  22. Ustekinumab for moderately to severely active Crohn's disease after previous treatment (TA456)

    Evidence-based recommendations on ustekinumab (Stelara) for previously treated moderately to severely active Crohn’s disease in adults

  23. Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people (TA455)

    Evidence-based recommendations on adalimumab (Humira), etanercept (Enbrel) and ustekinumab (Stelara) for treating plaque psoriasis in children and young people

  24. Uterine suspension using mesh (including sacrohysteropexy) to repair uterine prolapse (IPG584)

    Evidence-based recommendations on uterine suspension using mesh (including sacrohysteropexy) to repair uterine prolapse in women